Safety of Immune Checkpoint Inhibitors in Cancer Patients With Preexisting Autoimmune Vasculitis
Objective Immune checkpoint inhibitors (ICIs) are effective cancer therapies but often cause serious immune‐related adverse events (irAEs). Patients with preexisting autoimmune diseases, including vasculitis, are excluded from trials. We aimed to evaluate the frequency, severity, and outcomes of vas...
Salvato in:
| Autori principali: | , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wiley
2026-03-01
|
| Serie: | ACR Open Rheumatology |
| Accesso online: | https://doi.org/10.1002/acr2.90003 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|